MedTrace Logo

Rocuronium Dose Finding Study After Single-shot or Steady-state Propofol Anesthesia

NCT02054468 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2014-05-08

No results posted yet for this study

Summary

This study is designed to determine the effective-doses ED-50 and ED-95 (the doses required for a 50% and 95% twitch inhibition, respectively) of the non-depolarizing muscle relaxant rocuronium after single-shot or steady-state propofol anesthesia in a clinical setting.

Conditions

  • Neuromuscular Blockade
  • Anesthesia

Interventions

DRUG

Single-Shot Propofol

Single-shot propofol induction dose (1.5-2.5mg/kg body mass)

DRUG

30min infusion Propofol

30min of propofol infusion (4-6mg/kg/h)

DRUG

Remifentanil infusion

Remifentanil infusion (0.1-0.2µg/kg/min)

DRUG

Rocuronium (0.07mg/kg/body mass)

Rocuronium (0.07mg/kg/body mass)

DRUG

Rocuronium (0.1mg/kg/body mass)

Rocuronium (0.1mg/kg/body mass)

DRUG

Rocuronium (0.15mg/kg/body mass)

Rocuronium (0.15mg/kg/body mass)

DRUG

Rocuronium (0.2mg/kg/body mass)

Rocuronium (0.2mg/kg/body mass)

DRUG

Rocuronium (0.3mg/kg/body mass)

Rocuronium (0.3mg/kg/body mass)

DRUG

Rocuronium (0.45mg/kg/body mass)

Rocuronium (0.45mg/kg/body mass)

Sponsors & Collaborators

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Manfred Blobner, M.D. · Klinik für Anaesthesiologie, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675 München, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02054468 on ClinicalTrials.gov